Covered recipient · General Payments record
JOHN NIVEN
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$5.92
1 record · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Education | $5.92 | 1 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $5.92 | 1 |
Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JOHN NIVEN
NPI 1336167634 · CMS profile ID 60481
Allopathic & Osteopathic Physicians / Dermatology
MIAMI BEACH, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1336167634?year=2020&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JOHN NIVEN, NPI 1336167634, CMS profile ID 60481. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1336167634?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). JOHN NIVEN, NPI 1336167634, CMS profile ID 60481. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1336167634?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- JOHN NIVEN, NPI 1336167634, CMS profile ID 60481, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1336167634?year=2020&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
1 matching record · $5.92 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–1 of 1.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| PFIZER INC. | $5.92 | 10/22/2020 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743814049 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020
- Generated from
- OP_DTL_GNRL_PGYR2020_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $547,115.16 | 88 |
| PY2024 | Principal investigator | $919,823.31 | 487 |
| PY2023 | Recipient | $1,200.00 | 1 |
| PY2023 | Principal investigator | $635,503.38 | 419 |
| PY2022 | Principal investigator | $475,737.00 | 87 |
| PY2021 | Principal investigator | $161,162.86 | 33 |
| PY2020 | Principal investigator | $161,071.72 | 49 |
| PY2019 | Principal investigator | $202,395.85 | 23 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
88 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $1,529.40 | 12/31/2025 | Non-covered Recipient Entity LENUS RESEARCH | A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata | No dispute reported | 06/30/2026 | 1202534497 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $29,050.00 | 12/26/2025 | Non-covered Recipient Entity Interspond, Llc | A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) | No dispute reported | 06/30/2026 | 1235996543 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $170.00 | 12/24/2025 | Non-covered Recipient Entity INTERSPOND LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246432783 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,933.49 | 12/17/2025 | Non-covered Recipient Entity LENUS RESEARCH AND MEDICAL GRO | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223289870 |
| Principal investigator 1 | ABBVIE INC. | $572.50 | 12/04/2025 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202528714 |
| Principal investigator 1 | ABBVIE INC. | $12,338.84 | 12/04/2025 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202528716 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,327.84 | 12/04/2025 | Non-covered Recipient Entity INTERSPOND LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246432775 |
| Principal investigator 1 | Incyte Corporation | $2,500.00 | 12/01/2025 | Non-covered Recipient Entity INTERSPOND, LLC | A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240540616 |
| Principal investigator 1 | Incyte Corporation | $3,789.00 | 12/01/2025 | Non-covered Recipient Entity INTERSPOND, LLC | A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240540640 |
| Principal investigator 1 | Incyte Corporation | $2,000.00 | 12/01/2025 | Non-covered Recipient Entity INTERSPOND, LLC | A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240540648 |
| Principal investigator 1 | Incyte Corporation | $1,616.00 | 12/01/2025 | Non-covered Recipient Entity INTERSPOND, LLC | A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240540652 |
| Principal investigator 1 | Incyte Corporation | $26,000.00 | 12/01/2025 | Non-covered Recipient Entity INTERSPOND, LLC | A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240540660 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,885.09 | 12/01/2025 | Non-covered Recipient Entity LENUS RESEARCH AND MEDICAL GRO | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289015 |
| Principal investigator 1 | Incyte Corporation | $2,061.00 | 11/19/2025 | Non-covered Recipient Entity INTERSPOND, LLC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240540590 |
| Principal investigator 1 | Incyte Corporation | $1,842.00 | 11/19/2025 | Non-covered Recipient Entity INTERSPOND, LLC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240540608 |
| Principal investigator 1 | Incyte Corporation | $1,842.00 | 11/19/2025 | Non-covered Recipient Entity INTERSPOND, LLC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240540611 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 11/19/2025 | Non-covered Recipient Entity INTERSPOND, LLC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240540620 |
| Principal investigator 1 | Incyte Corporation | $1,939.00 | 11/19/2025 | Non-covered Recipient Entity INTERSPOND, LLC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240540632 |
| Principal investigator 1 | Incyte Corporation | $108.00 | 11/19/2025 | Non-covered Recipient Entity INTERSPOND, LLC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240540644 |
| Principal investigator 1 | Incyte Corporation | $63.00 | 11/19/2025 | Non-covered Recipient Entity INTERSPOND, LLC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240540656 |
| Principal investigator 1 | ABBVIE INC. | $1,415.00 | 11/05/2025 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202521325 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,021.92 | 10/22/2025 | Non-covered Recipient Entity LENUS RESEARCH AND MEDICAL GRO | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223287253 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $5,449.07 | 10/10/2025 | Non-covered Recipient Entity INTERSPOND LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246432763 |
| Principal investigator 1 | ABBVIE INC. | $8,127.50 | 10/09/2025 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202516237 |
| Principal investigator 1 | ABBVIE INC. | $4,855.00 | 10/09/2025 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202516239 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 10/09/2025 | Non-covered Recipient Entity INTERSPOND, LLC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240540595 |
| Principal investigator 1 | Incyte Corporation | $108.00 | 10/09/2025 | Non-covered Recipient Entity INTERSPOND, LLC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240540599 |
| Principal investigator 1 | Incyte Corporation | $63.00 | 10/09/2025 | Non-covered Recipient Entity INTERSPOND, LLC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240540628 |
| Principal investigator 1 | Incyte Corporation | $2,061.00 | 10/09/2025 | Non-covered Recipient Entity INTERSPOND, LLC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240540672 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $34,140.65 | 10/08/2025 | Non-covered Recipient Entity LENUS RESEARCH & MED GRP | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190310432 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $992.00 | 10/08/2025 | Non-covered Recipient Entity INTERSPOND LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246432750 |
| Principal investigator 1 | ABBVIE INC. | $6,022.20 | 10/02/2025 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202513131 |
| Principal investigator 1 | Incyte Corporation | $3,789.00 | 10/02/2025 | Non-covered Recipient Entity INTERSPOND, LLC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240540603 |
| Principal investigator 1 | Incyte Corporation | $26,000.00 | 10/02/2025 | Non-covered Recipient Entity INTERSPOND, LLC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240540624 |
| Principal investigator 1 | Incyte Corporation | $1,616.00 | 10/02/2025 | Non-covered Recipient Entity INTERSPOND, LLC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240540636 |
| Principal investigator 1 | Incyte Corporation | $2,000.00 | 10/02/2025 | Non-covered Recipient Entity INTERSPOND, LLC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240540664 |
| Principal investigator 1 | Incyte Corporation | $2,500.00 | 10/02/2025 | Non-covered Recipient Entity INTERSPOND, LLC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240540668 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $13,358.52 | 09/26/2025 | Non-covered Recipient Entity LENUS RESEARCH AND MEDICAL GROUP LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285979 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,933.77 | 09/17/2025 | Non-covered Recipient Entity LENUS RESEARCH AND MEDICAL GROUP LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223285616 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $255.00 | 09/11/2025 | Non-covered Recipient Entity INTERSPOND LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246432739 |
| Principal investigator 1 | ABBVIE INC. | $12,750.00 | 09/04/2025 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202509744 |
| Principal investigator 1 | ABBVIE INC. | $6,424.52 | 09/03/2025 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202508128 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,383.68 | 09/03/2025 | Non-covered Recipient Entity LENUS RESEARCH AND MEDICAL GROUP LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285033 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $4,991.76 | 08/20/2025 | Non-covered Recipient Entity INTERSPOND LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246432725 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,760.23 | 08/15/2025 | Non-covered Recipient Entity LENUS RESEARCH AND MEDICAL GROUP LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223284353 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,558.89 | 08/13/2025 | Non-covered Recipient Entity LENUS RESEARCH AND MEDICAL GROUP LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223284223 |
| Principal investigator 1 | ABBVIE INC. | $7,150.00 | 08/06/2025 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202503147 |
| Principal investigator 1 | ABBVIE INC. | $2,893.00 | 08/05/2025 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202501820 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $85.00 | 07/28/2025 | Non-covered Recipient Entity INTERSPOND LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246432713 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $170.00 | 07/28/2025 | Non-covered Recipient Entity INTERSPOND LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246432717 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,623.75 | 07/23/2025 | Non-covered Recipient Entity LENUS RESEARCH AND MEDICAL GROUP LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223283024 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,293.88 | 07/09/2025 | Non-covered Recipient Entity LENUS RESEARCH AND MEDICAL GROUP LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223282424 |
| Principal investigator 1 | ABBVIE INC. | $7,150.00 | 07/08/2025 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202497024 |
| Principal investigator 1 | ABBVIE INC. | $5,254.00 | 07/02/2025 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202495085 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $255.00 | 07/01/2025 | Non-covered Recipient Entity INTERSPOND LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246432695 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $5,543.59 | 06/18/2025 | Non-covered Recipient Entity INTERSPOND LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246432686 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $85.00 | 06/13/2025 | Non-covered Recipient Entity INTERSPOND LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246432678 |
| Principal investigator 1 | ABBVIE INC. | $2,361.00 | 06/11/2025 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202490905 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,473.45 | 06/04/2025 | Non-covered Recipient Entity LENUS RESEARCH AND MEDICAL GROUP LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223280708 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $26,030.76 | 06/04/2025 | Non-covered Recipient Entity LENUS RESEARCH AND MEDICAL GROUP LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223280728 |
| Principal investigator 1 | ABBVIE INC. | $3,775.00 | 06/03/2025 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202489627 |
| Principal investigator 1 | ABBVIE INC. | $4,500.00 | 06/02/2025 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202487291 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,663.92 | 05/27/2025 | Non-covered Recipient Entity INTERSPOND LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246432669 |
| Principal investigator 1 | ABBVIE INC. | $7,150.00 | 05/07/2025 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202483221 |
| Principal investigator 1 | ABBVIE INC. | $4,500.00 | 05/07/2025 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202483291 |
| Principal investigator 1 | ABBVIE INC. | $9,316.10 | 05/07/2025 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202483293 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $16,743.72 | 05/07/2025 | Non-covered Recipient Entity LENUS RESEARCH AND MEDICAL GROUP LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223279136 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,555.00 | 04/16/2025 | Non-covered Recipient Entity LENUS RESEARCH AND MEDICAL GROUP LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223278166 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,327.84 | 04/15/2025 | Non-covered Recipient Entity INTERSPOND LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246432657 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,459.00 | 04/07/2025 | Non-covered Recipient Entity INTERSPOND LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246432647 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $85.00 | 04/07/2025 | Non-covered Recipient Entity INTERSPOND LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246432652 |
| Principal investigator 1 | ABBVIE INC. | $5,124.26 | 04/03/2025 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202472981 |
| Principal investigator 1 | ABBVIE INC. | $3,575.00 | 04/03/2025 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202473211 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,122.97 | 04/02/2025 | Non-covered Recipient Entity LENUS RESEARCH AND MEDICAL GROUP LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223277490 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $2,215.75 | 03/24/2025 | Non-covered Recipient Entity INTERSPOND LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246432639 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $170.00 | 03/21/2025 | Non-covered Recipient Entity INTERSPOND LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246432630 |
| Principal investigator 1 | ABBVIE INC. | $9,450.52 | 03/07/2025 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202460817 |
| Principal investigator 1 | ABBVIE INC. | $14,300.00 | 03/07/2025 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202460820 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $12,552.88 | 03/07/2025 | Non-covered Recipient Entity LENUS RESEARCH AND MEDICAL GROUP | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223276149 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,327.84 | 03/03/2025 | Non-covered Recipient Entity INTERSPOND LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246432625 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $14,447.13 | 03/03/2025 | Non-covered Recipient Entity LENUS RESEARCH AND MEDICAL GROUP | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223275907 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $23,093.15 | 02/14/2025 | Non-covered Recipient Entity LENUS RESEARCH AND MEDICAL GROUP | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223275343 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,663.92 | 02/07/2025 | Non-covered Recipient Entity INTERSPOND LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246432617 |
| Principal investigator 1 | ABBVIE INC. | $5,902.50 | 02/06/2025 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202447936 |
| Principal investigator 1 | ABBVIE INC. | $6,416.14 | 02/06/2025 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202448069 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $24,660.22 | 02/05/2025 | Non-covered Recipient Entity LENUS RESEARCH AND MEDICAL GROUP | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223274945 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $170.00 | 01/17/2025 | Non-covered Recipient Entity INTERSPOND LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246432605 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $255.00 | 01/17/2025 | Non-covered Recipient Entity INTERSPOND LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246432609 |